Pediatric Drug Labeling and Imperfect Information

Area of Science:

• Medical Ethics
• Pediatric Pulmonology
• Drug Regulation

Background:

• The author's initial encounter with bioethics occurred during medical training in 1980.
• A realization that clinical decisions, even those appearing technical, possess ethical dimensions.
• A forty-year journey from aspiring pediatrician to pediatric pulmonologist involved in regulatory ethics.

Purpose of the Study:

• To explore the implicit ethical issues within clinical care.
• To reflect on the ethical dimensions of drug labeling regulation.
• To connect personal experiences with the field of bioethics.

Main Methods:

• Personal reflection on a forty-year career in medicine.
• Observation of ethical considerations in clinical decision-making.
• Participation in the U.S. Food and Drug Administration's Pediatric Advisory Committee meetings.

Main Results:

• Clinical decisions, including drug regulation, are deeply intertwined with ethical questions.
• The author experienced a consistent sense of awe and curiosity regarding ethical issues in medicine over four decades.
• Discussions on drug labeling changes revealed significant ethical complexities.

Conclusions:

• Bioethics is a pervasive element in medical practice and drug regulation.
• Ethical considerations in pediatrics require careful attention, particularly in drug labeling.
• The intersection of clinical practice, regulation, and ethics remains a vital area of study.